Key Details
Price
$270.61Annual ROE
199.53%Beta
0.56Events Calendar
Next earnings date:
Feb 13, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Investors can increase their returns by including these highly-rated liquid stocks, such as Alnylam Pharmaceuticals, Frontdoor, EverQuote, and Sezzle, in their portfolios.
On January 27, 2024, ALNY, HBT, APH, GNTY, and OSUR were included in the Zacks Rank #1 (Strong Buy) List.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
On January 21, 2025, CDNA, AVXL, and ALNY were included in the Zacks Rank #1 (Strong Buy) list of momentum stocks.
Alnylam Pharmaceuticals is expected to see growth in 2025 due to its commercialization efforts and early-stage research. These factors are likely to play a significant role in the company's success.
This is a comparison of how Alnylam Pharmaceuticals (ALNY) and argenx SE (ARGX) have done in relation to their industry up to this point in the year.
Alnylam (ALNY) has received a Zacks Rank #2 (Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a top company in RNAi therapeutics, has announced that its management will give a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 11:00 am ET, held at the Lotte New York Palace Hotel in New York City. You can listen to a live audio webcast of the presentation on the Investors section of the company's website at www.alnylam.com/events, and a replay will also be accessible.
ALNY has announced that it has submitted a supplemental New Drug Application (sNDA) in the United States. This application aims to expand the use of Amvuttra for treating ATTR amyloidosis that affects the heart.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a top company in RNAi therapeutics, has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), which is being developed to treat transthyretin (ATTR) amyloidosis. The results were presented during an oral session at the American Heart Association Scientific Sessions 2024 in Chicago. These findings showed that a single dose of the treatment had significant effects.
FAQ
- What is the primary business of Alnylam Pharmaceuticals?
- What is the ticker symbol for Alnylam Pharmaceuticals?
- Does Alnylam Pharmaceuticals pay dividends?
- What sector is Alnylam Pharmaceuticals in?
- What industry is Alnylam Pharmaceuticals in?
- What country is Alnylam Pharmaceuticals based in?
- When did Alnylam Pharmaceuticals go public?
- Is Alnylam Pharmaceuticals in the S&P 500?
- Is Alnylam Pharmaceuticals in the NASDAQ 100?
- Is Alnylam Pharmaceuticals in the Dow Jones?
- When was Alnylam Pharmaceuticals's last earnings report?
- When does Alnylam Pharmaceuticals report earnings?
- Should I buy Alnylam Pharmaceuticals stock now?